CALDOLOR SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

IBUPROFEN

Inapatikana kutoka:

CUMBERLAND PHARMACEUTICALS INC

ATC kanuni:

M01AE01

INN (Jina la Kimataifa):

IBUPROFEN

Kipimo:

100MG

Dawa fomu:

SOLUTION

Tungo:

IBUPROFEN 100MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

250ML

Dawa ya aina:

Prescription

Eneo la matibabu:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0108883008; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2019-09-11

Tabia za bidhaa

_Caldolor_
_® _
_Product Monograph _
_Page 1 of 31_
PRODUCT MONOGRAPH
PR
CALDOLOR
®
Ibuprofen for Intravenous Injection
100 mg/mL
Nonselective Cyclooxygenase Inhibitor
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Alveda Pharmaceuticals Inc
40 Holly Street, Suite 801
Toronto ON M4S 3C3
DATE OF PREPARATION:
MAY 14, 2012
SUBMISSION CONTROL NO: 147713
_Caldolor_
_® _
_Product Monograph _
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND
ADMINISTRATION..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND
STABILITY..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..........................................................................................